Figure 1.
Flow chart summarising multi-country enrolment of dengue patients and basis for the final dataset.
Table 1.
List of laboratories performing diagnostic testing for the patients enrolled in the DENCO study.
Table 2.
Laboratory criteria employed at country level for dengue laboratory classification as confirmed dengue case.*
Figure 2.
Sensitivity of kits Pan-E and Platelia.
Shown are the sensitivities (±95% CI) of kits Pan-E and Platelia assays from six Asian and Latin-American countries in 1385 patients with a laboratory confirmed diagnosis of dengue (A) and sensitivities in the subgroup of 933 patients confirmed by PCR or viral isolation (B).
Figure 3.
NS1 sensitivity by day of illness.
(A) Shown is the sensitivity (±95% CI) of kits Pan-E and Platelia by day of illness in four Asian countries (N = 728 -kit Pan-E; N = 1152 -kit Platelia) amongst patients with a laboratory confirmed diagnosis of dengue where the acute sera were collected between day 2 and day 6 of illness. (B) Shown is the sensitivity (±95% CI) of kits Pan-E and Platelia in the first four days of illness in two Latin American countries (N = 93 -kit Pan-E; N = 90 -kit Platelia) amongst patients with a laboratory confirmed diagnosis of dengue where the acute sera were collected between day 2 and day 4 of illness. Data is presented for those days of illness with > = 40 observations respectively.
Table 3.
NS1-sensitivity in the context of DENV serotype.
Table 4.
Geographical and serotype stratification of the study population.
Table 5.
NS1 detection (kit Platelia assay only) in relation to IgM status and day of illness.*
Table 6.
Sensitivity of Kit Platelia and Pan-E by geographic region and disease severity.*
Table 7.
NS1 results as determined by Kit Pan-E and Platelia assays in control sera panels.